A growing body of evidence indicated that TGF-β1, CTGF, and ET-1 expressions are cooperatively augmented within the lung tissue in IPF [38, 39], supporting that TGF-β/CTGF or ET-1 axis serves as the potential target for anti-fibrotic therapy. The gene discussed is EDN1; the disease is idiopathic pulmonary fibrosis.